In every country, a manufacturer of medicinal products for either human or veterinary use is required to operate in compliance with local legislation. In all EU Member States, legislation is approximated to the effect that they are committed to abide by the same standards. The candidate countries transpose the acquis into their national legislation, including the good manufacturing practice (GMP). Consequently, the local manufacturer is required to strictly comply with GMP and the manufacturing licence, including for medicinal products exclusively intended for export. A vital role is also played by national regulatory authorities, in Croatia by the Agency for Medicinal Products and Medical Devices which issues the manufacturing licence, GMP certifi cate, and the Certifi cate of a Pharmaceutical Product (CPP) and conducts laboratory control of products. GMP inspection is carried out by the Pharmaceutical Inspectorate with the Ministry of Health and Social Welfare. Both authorities are responsible only for human medicines. There are legislative issues not yet harmonised with the acquis, but as a country aspiring for the EU membership, Croatia is expected to demonstrate that its industry and competent authorities are able to conform to current requirements and thus fully adhere to the integrated European regulatory network. Hence the importance of strengthening the institutional capacity of the competent authorities, as insuffi cient resources may have a direct bearing on patients by limiting their access to affordable treatment.
Today we are facing diffi culties in securing a safe production and distribution chain for medicinal products. This is exemplifi ed by recent occurrences of contaminated heparin (1) causing severe anaphylactoid reactions, or the global recall of nelfi navir (Viracept ® ) due to contamination with ethyl methanesulfonate (2) . Furthermore, the ever increasing presence of counterfeit medicines, also in the EU, poses a serious risk to public health (3, 4) . Pharmaceutical manufacturers are obligated to apply GMP standards with strong emphasis on quality assurance and quality control (QA/QC) within the production process. Since the output is a human medicine, QA/QC procedures monitor and test the production process carefully to ensure that no patients will be harmed (5) . The Croatian manufacturers and competent authorities are implementing the acquis which has been adopted into national legislation. In this pre-accession period there are still discrepancies in terms of the roles of manufacturers and the Agency responsible for medicines locally produced and those produced in other countries, including the EU (6) . This article analyses the role of competent authorities, particularly of the Agency for Medicinal Products and Medical Devices (Agency), in the supervision of drug production and quality assurance, as well as the role of the Pharmaceutical Inspectorate. The Agency is assigned the important task of granting GMP certifi cates for products manufactured in Croatia, granting certificates of pharmaceutical products (CPPs), granting manufacturing licences to local manufacturers and withdrawing them when needed, and conducting quality control of products entering the country and retesting them by taking samples from pharmacy shelves.
GOOD MANUFACTURING PRACTICE
The concept of good manufacturing practice (GMP) is applied to any activities involving production management and operation. It is indispensable in pharmaceutical production, and its principles must be observed at all stages, from the production of active substances to the fi nished product. Patients expect to get a safe, effi cient and quality medicinal product (7, 8) . GMP is intended to ensure drug production that would consistently meet all these requirements. Traditionally, drug manufacturers have relied on quality control (QC) procedures, based on the concept of testing the fi nished product for compliance with specifi cations, which in itself, however, is no guarantee that the product will possess the desired quality. For that reason, current procedures include quality assurance (QA) with emphasis on quality, from design to the fi nished product. QA/QC are a part of GMP that provides effi cacious drug production and distribution systems within an appropriate environment and by trained and qualifi ed personnel.
Qualifi ed personnel
A qualified personnel includes production operations and quality control people. In addition, the manufacturer is required to provide a suffi cient number of trained quality assurance people. This in the fi rst place refers to people qualifi ed for batch (lot) release, as they issue certifi cates for placing production batches on the market. Qualifi ed person should be a university graduate educated in subjects specifi ed in the Directive 2001/83/EC (9) . In Croatia, these requirements best correspond to the Pharmacy Graduates, who are additionally specialised in drug testing and control for three years, or should have at least fi ve-year experience in relevant jobs to qualify for such a position (6) .The EU demands only two years of relevant experience. According to Croatian legislation (10) a qualifi ed person for batch release in cases of the manufacture of specifi c medicinal products (biologics, radiopharmaceuticals, medical gases) and pharmaceutical forms may also graduated in medicine, veterinary medicine, chemistry, biology and other scientifi c disciplines, but should possess at last fi ve-year experience in pharmaceutical quality control. The qualifi ed person is a person responsible to release each batch of medicinal products for marketing (11) .
Production premises and equipment
Production premises and equipment should be located, designed and managed in a way which will minimise the risk of error and facilitate effi cient cleaning and maintenance with a view to avoiding contamination, cross contamination, and any other undesired effects on product quality. Likewise, premises and equipment used in production are critical for product quality and they should be properly qualifi ed and validated (12) .
Documentation
The manufacturer should establish and maintain a record-keeping system based on product quality requirements, pharmaceutical manufacturing formulations, manufacturing instructions, fi nished pharmaceutical product packaging instructions, operating procedures, and records covering different production processes in order to demonstrate that operations are carried out in conformance with GMP. Records must be clear, without mistakes, and updated. Batch documentation should be kept for at least one year after the expiry date of the batch concerned or fi ve years after placing a batch on the market, whichever comes later. Different production procedures should be carried out according to pre-established written instructions and procedures and in line with GMP. Any deviations from the established procedures and any damage to the product should be properly documented and thoroughly investigated. To avoid cross contamination or submixing, all necessary technical and organisational measures should be taken. Each new production procedure or major modifi cation of the existing production procedure should be validated. The critical stages of a production procedure must be re-validated at regular intervals (13) .
Process analytical technology
Process analytical technology (PAT) has been defined by the United States Food and Drug Administration (FDA) as a mechanism to design and control pharmaceutical manufacturing processes through the measurement of critical quality parameters within given timeframes, aimed to assure the finished product quality. The PAT concept is aimed at understanding production by defi ning its critical process parameters and by monitoring them (preferably in-line or on-line). This ensures greater testing effi ciency, reduces over-processing, enhances consistency, and minimizes rejects. The concept is designed for the manufacturer to identify and measure all quality impact factors, so that the fi nished product fulfi ls its pre-defi ned characteristics from the start of production, which is also referred to as quality by design. Even though PAT activities are not a current requirement of the GMP in the EU, in 2003, the EMA created a forum for dialogue and understanding with the aim of reviewing the implications of PAT and ensuring that the European regulatory framework and authorities are prepared for and adequately equipped to conduct thorough and effective evaluations of PAT-based submissions. The EMA believes that the current regulatory framework in Europe is open to the implementation of PAT in marketing authorisation applications. Moreover, the International Conference on Harmonisation Guideline on Pharmaceutical Development (ICH Q8), which includes provisions on the use of PAT applications, has also been adopted by the EU.
Quality control
The manufacturer should establish and maintain a quality control system run by a qualifi ed person independent of production. This person should have at his or her disposal one or more quality control laboratories staffed and equipped to test starting and packaging materials, intermediate and fi nished products. To this end the services of other qualifi ed laboratories may be used, i.e. those meeting GMP requirements, which are authorised in the procedure for granting the manufacturing license, and with which the manufacturer has a valid written contract. The fi nal checking of fi nished medicinal products, before placing them on the market, should take into account not only analytical results, but all other relevant information such as production conditions, results of process control, production documentation, and whether the product meets the set quality requirements, including its fi nal packaging (14, 15) .
Complaints and recalls
The manufacturer should establish a system of labelling and evaluating all complaints related to product defects and an efficient system to recall defective medicinal products. Finished products should be labelled and isolated pending checks for conformity to product specifi cation. QA procedures should ensure that a defective fi nished product is an exception. The manufacturer must notify local competent authorities and, if possible, the country of destination of any product defect that may result in its recall or in restricted application (16, 17) .
Self-inspection
The QA system requires that the manufacturer monitors and oversees compliance with GMP and proposes measures to improve the QA system. Selfinspection is internal and a record is kept for all inspections and corrective measures (18) .
COMPETENT AUTHORITIES

Agency for Medicinal Products and Medical Devices
Competent authorities for GMP for medicinal products for human use in Croatia are the Agency for Medicinal Products and Medical Devices and the Ministry of Health and Social Welfare's Pharmaceutical Inspection Department. The Agency grants the manufacturing license, certifi cate of a pharmaceutical product (CPP), and good manufacturing practice certifi cate ( Figure 1 ) and the Ministry verifi es compliance with GMP/GDP (Good Distribution Practice), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and conducts pharmacovigilance inspection.
Procedure for granting manufacturing licence Manufacturing licence is not required for making extemporaneous and galenic formulations at pharmacies or laboratories, but it is for industrial drug production. Agency appoints a technical commission which makes an inspection to verify that the manufacturer meets GMP requirements. The technical commission consists of pharmaceutical inspectors and experts in relevant fi elds. Pharmaceutical inspectors issue a written opinion based on inspection report and, in the event of defi ciencies found at inspection, also based on the applicant's response to the report. In its report, inspection encourages the manufacturer to set in motion its corrective and preventive action (CAPA) system. The aim of the CAPA systems is to ensure that defi ciencies/deviations/ non-conformance, product complaints, external and internal audit observations, annual product reviews, recommendations, and regulatory issues are identifi ed, fully investigated to their root cause, and properly assessed by the manufacturer. If the applicant does not meet all the prescribed GMP requirements, the Agency may grant a temporary manufacturing licence for a term shorter than fi ve years (6, 10) .
GMP certifi cate
The holder of the manufacturing licence may apply for a GMP certifi cate that generally summarises the contents of the manufacturing license in one page. According to Croatian legislation, the issuance of the certifi cate is subject to meeting GMP requirements laid down in the procedure of issuing the manufacturing licence or to a satisfactory on-site audit by the pharmaceutical inspector. However, Directive 2001/83/ EC (9) stipulates that an inspection is required before any GMP certifi cate is granted. If inspection verifi es GMP compliance, the certifi cate is granted within 90 days.
The certificate for a medicinal product or pharmaceutical form granted by the Agency specifi es the place of production, production facility or facilities, and parts of the production process. GMP certifi cate does certify manufacturer's capability to maintain the consistency in the quality of an active pharmaceutical ingredient, so it is vital that on-site audits are performed. If an application for a GMP certifi cate is submitted three years or more since the manufacturing licence was issued or since the latest audit was performed, the Agency will seek an opinion from the pharmaceutical inspectorate as to confi rm whether GMP requirements have been met (10, 19) .
Certifi cate of a pharmaceutical product
The certifi cate of a pharmaceutical product (CPP) is a voluntary certification scheme set up by the World Health Organization (WHO) and is issued by competent national authorities upon request from either the local manufacturer, the customer, or the authorities in the importing country. The certifi cate is issued for a specifi c product and indicates whether or not the product is marketed in the country of origin. Furthermore, it states that the manufacturer complies with GMP and that the pharmaceutical product is inspected regularly by the competent national authority.
CPP issued by the Agency provides a partial assurance to countries with limited drug regulatory capacity that a pharmaceutical product which they plan to import is safe, effective, and of good quality.
Sampling and testing programme
Any medicinal product, either imported or locally manufactured, to be marketed in Croatia must hold the Agency's marketing authorisation. The manufacturer
Figure 1 Certifi cates of a pharmaceutical product (CPP), good manufacturing practice certifi cates (GMP) and manufacturing
licenses granted by the Agency must ensure that all production procedures are in compliance with data submitted to the Agency when applying for marketing authorisation of a fi nished product. Croatia-based manufacturers need to verify the quality of each batch of a fi nished product that is to be released for marketing in Croatia. For fi nished medicinal products imported to Croatia, it is the responsibility of the importer to verify that they comply with GMP. At the request of the competent authority, the importer must provide evidence that the product has been manufactured by a manufacturer holding the manufacturing licence. Both the local manufacturer and the importer are required to submit to the Agency samples of every fi rst manufactured or imported batch for quality control. The Agency's approval of every batch imported from the EU is based on a certifi cate of analysis endorsed by a EU qualifi ed person (QP) (Figure 2 ). Both the analysis of the fi rst batch and the issuance of approval for imported batches from a single European market will cease to apply when Croatia becomes the EU member state, because they would be in contravention of the free movement of goods. Besides, medicinal products in the EU which are properly controlled and released for marketing by a QP do not have to be retested by any competent authority in the EU. Hence the Agency will steer its quality control towards the so-called riskbased approach of taking samples from the market.
This principle of off-the-shelf drug testing is also practised in this pre-accession period, where every medicinal product is taken off the shelves once in fi ve years for testing by the Agency. In case of any doubt about the quality of a medicinal product or reported adverse effects, such a product may be ad hoc sampled and retested. If it is a third-country product, samples of each imported batch should be submitted to the Agency for testing (6) .
The role of the inspector
GMP inspectors must be highly trained in all relevant areas of QA/QC management, production procedure, drug control, and distribution and inspection methodology (20) . Apart from the EMA guidelines on the training and qualifications of GMP inspectors, each country may have additional requirements. In Croatia these are defi ned by a special ordinance (21) . It is desirable that an inspector has qualifi cations as specifi ed for the qualifi ed person referred to in Directive 2001/83/EC (9) for human medicinal products and in Directive 2001/82/EC (22) for veterinary medicinal products. It is necessary to constantly assess the educational needs of inspectors and take steps to improve their skills. Organisationally, the GMP inspectorates in the Member States, with the exception of Germany, The Netherlands, and Poland, are attached to the national medicines agencies, Figure 2 Batch release of locally manufactured and imported batches in Croatia according to local legislation (6) which makes them a constituent part of an integrated regulatory system. In Croatia, the Agency is responsible for the issuance of manufacturing licences, GMP and CPP certifi cates, whereas the GMP audit itself is the responsibility of the Pharmaceutical Inspectorate of the Ministry of Health and Social Welfare. Furthermore, the Inspectorate for Veterinary Medicinal Products is part of the Veterinary Directorate at the Ministry of Agriculture, Forestry and Rural Development. The inspectorate for human medicines performs regular and extraordinary inspections of drug manufacturers. Regular inspections are performed every two to three years. Extraordinary inspections are undertaken in case of incident situations, serious complaints, product recalls, product defects detected by the Agency, doubts about product quality or signs of unusual occurrences and other circumstances, with an aim to ensure product quality. Serious non-compliance by defi nition requires administrative action to be taken by the inspector.
Quality defects and batch recalls
Every health care professional, physician, or pharmacist is required to report a defective medicinal product to the Agency, which, depending on the degree of urgency, takes appropriate action that may include recalling the product from the market (23) . Batches or marketing authorisation may also be suspended due to pharmacovigilance issues, where an unexpected signal of an adverse drug reaction or unexpected grouping of signals linked to certain batches occurs. Every marketing authorisation holder in Croatia should have in place an efficient product recall procedure and report recall to the Agency and relevant authorities in other countries. The Agency informs the public and health care services about the recall of defective products on its web pages and through the National Information Centre, which is responsible for immediately informing hospitals and other health care institutions. In 2009, only fi ve batches were recalled from the Croatian market, compared with 15 in 2007. In most cases, however, product batches are recalled by the manufacturer himself, who notifi es the Agency of suspected defects.
INTERNATIONAL CO-OPERATION
European Economic Area (EEA)
The European Medicines Agency (EMA) is responsible for the maintenance and public release of (9, 22, 25) , an inspector of a Member State competent authority inspects on behalf of the entire EU and these inspections are supposed to be mutually recognised by all Member States. Information obtained during GMP inspections should be kept confi dential by inspectors, in accordance with the EU, national, and international laws and agreements. Inspections by a Member State competent authority are carried out on behalf of the entire EU, because GMP non-compliance may have an impact on other Member States. Competent national authorities must take into account information on serious GMP non-compliance received and should follow recommended actions, where the procedures requires to do so, unless their competent authorities can justify alternative courses of action based on specifi c national considerations, provided that they have no impact on other Member States. With regard to actions, direct or consequential, against marketing authorisations, the Reference Member State 1 takes initiative for mutual recognition. EMA co-ordinates action regarding centrally authorised products. Each competent national authority takes the responsibility for marketing authorisations on national level alone. The reporting inspectorate should enter information on serious GMP non-compliance in the Eudra GMP telematic system. The procedure requires that the inspectorate discovering serious GMP non-compliance should recommend appropriate action, involving other authorities that share supervisory responsibility in developing such recommendations, and communicate their recommendations to all other authorities in the EU, European Directorate for the Quality of Medicines and Health Care (EDQM), and to countries that have signed a mutual recognition agreement (MRA), Pharmaceutical Inspection Convention / Scheme (PIC/S), (26, 27) and New Collaboration Agreement between Drug Regulatory Authorities in Central and Eastern Europe (nCADREAC).
European Directorate for the Quality of Medicines and Health Care
European Directorate for the Quality of Medicines and Health Care (EDQM) issues the Certifi cate of European Pharmacopoeia (CEP), established in 1994. Initially it was limited to active substances, but since 1999 it has included products that pose a risk of transmissible spongiform encephalopathy (TSE). This certifi cation procedure ensures the quality of active substances and excipients and conformance to the European Pharmacopoeia. When applying for a marketing authorisation, the applicant may use CEP as a proof that the used substance conforms to the European Pharmacopoeia. Suspension or voiding of a CEP may be a recommended course of action following an inspection by EDQM of an active substance manufacturer who does not conform to GMP standards anymore. This procedure additionally addresses action to be taken by both manufacturers and regulators in the event of notifi cation by EDQM that a CEP has been voided or suspended (28) . There are procedural differences in suspension or cancellation of certifi cates between EDQM and FDA. If EDQM fi nds that an active pharmaceutical ingredient API fails to meet GMP requirements, it will set up an ad hoc committee to decide on CEP suspension. If FDA fi nds non-compliance, it will fi le a report on which the manufacturer must state its position. If the manufacturer's answers remain unsatisfactory, FDA will send him a warning letter. These two approaches demonstrate differences between the EU and US regulatory systems, where the latter decides based upon the manufacturer's statement, whereas in the EU, manufacturer is not involved in decision-making, but the decision is made by regulators alone.
Pharmaceutical Inspection Convention / Scheme
Pharmaceutical Inspection Convention (PIC) was established by the European Free Trade Association (EFTA) in 1970. It was an international treaty between 
DISCUSSION
In Croatia several manufacturers make medicinal products for human use in a variety of pharmaceutical forms, including capsules and tablets, semi-solid emulsions, parenteral solutions, lyophilised powders for intravenous and intramuscular administration, syrups, suspensions, and drops (Table 1) . These are medicines of all therapeutic groups, plus vaccines, blood components, and medicinal gases. Pharmaceutical industry in Croatia is largely generic, that is, it makes products similar to the ones whose patent protection has expired. With the exception of azithromycin, local manufacturers mainly import active substances and even fi nished formulations, and it is essential to make sure that GMP is maintained. Local manufacturers receive the manufacturing licence from the Agency for all sites in Croatia where their production takes place. Furthermore, the Agency issues GMP and CPP certifi cates upon request. These primarily serve for the export of individual batches abroad. Figure 1 shows that the number of issued GMP and CPP certifi cates dropped in 2009, which can be associated with recent acquisitions in Croatia that resulted in changes to the existing production portfolio of manufacturers. It is possible that the growth of issued GMP/CPP certificates depends on the vitality of the local pharmaceutical industry. Meanwhile, the number of issued production licences was increased, resulting from new generic drug companies that arose as greenfi eld investments in Croatia. Frequent variations in manufacturing license are an administrative burden, as the license in Croatia is granted for a medicinal product under the trade name, and not for a pharmaceutical form alone, which would be easier to handle, like in the EU countries. Globalisation and mere survival on the market push local manufacturers to export and therefore meet inspection requirements of other EU and non-EU countries (30) . For export to the EU countries it is necessary to obtain the EU GMP certifi cate, and Croatian manufacturers are for that purpose subject to inspection by Member State inspectorates. In Croatia, competence over GMP inspection and regulation is now split between the Ministry and the Agency, whereas in most countries it is a regulatory matter of the Agencies. If GMP inspection were to become the Agency's responsibility, certain administrative and other decisions would be easier to make, because the Agency has complete documentation about medicines and production and experts to evaluate medicinal products. Croatian inspectors participate in some of the meetings of EMA's GMP Inspectors Group and EudraGMP Telematics Groups, although in terms of preparation for EU membership they would benefi t much more from fi eld team training with their colleagues from the EU. For Croatia, PIC/S membership would contribute to the promotion of mutual exchange of information and resources.
Considering that most of active substance production has moved to lower-cost geographies, where it is not necessarily supervised by health authorities and where the likelihood of substandard medicines entering the supply chain is greater, it is necessary to inspect the place of active substance production in third countries (31) . Therefore, Croatian legislation will need additional provisions to defi ne the inspection of active substance manufacturers by the national authority. According to the current legislation, the Agency may inspect manufacturing sites abroad if that is necessary during the marketing authorisation procedure. However, inspection of active substance manufacturers will require further training of inspectors. This will facilitate exchange of information and mutual recognition of active substance inspection reports between Croatia and regulators in the integrated European network.
It is also important that Croatia is included in the Rapid Alert System before joining the EU in order to make the exchange of relevant and urgent information as quick as possible.
Croatia has local production of vaccine and blood components, including integrated active substance production. Vaccine manufacturing standards have been raised high and production requires strict supervision by the Agency. For vaccine manufacturers in developing countries the only possibility of survival on the international market is the WHO Prequalification Programme, which includes a positive assessment of both the manufacturer and the competent authority (32) , one that the Croatian Agency has already obtained. Local manufacturers have a qualifi ed person on staff and release batches to the Croatian market, with the exception of the fi rst production batch which may only be released to the market following analyses conducted by the Agency. If the intent is to export the product to the territory of the EU/EEA, the manufacturer must have a qualifi ed person for batch release there. Considering that Croatia is not yet a full member of the European Union, drug batches imported from the EU may not be automatically released on the Croatian market. However, in light of joining the common European market where all barriers to the free movement of goods will be eliminated and in light of the fact that no national agency can conduct a complete batch release analysis for each imported batch, the Agency advocates administrative release of batches imported from the EU in the manner that an analysis is not conducted, but instead the certifi cate of analysis and the content of the sales presentation are inspected for each imported batch. Pursuant to these, approval is granted for the import of the drug and batch release for the Croatian market. However, drug importers from the third countries are required to undergo Agency analysis for each imported batch (Figure 2 ).
CONCLUSION
As local manufacturers increase export, so does Agency's monitoring activity become increasingly internationalised. Besides, both the Agency and the manufacturers are adapting to market conditions that will prevail once Croatia becomes part of the single EU market. To this end, both sides are implementing EU Directives that Croatia has adopted and incorporated into its national legislation. As we move forward, it will become increasingly important to produce well trained inspectors. Every country has its own GMP rules. As regards inspections, what matters most is their regularity, effi cacy in enforcing GMP, and quick reporting on non-compliance. Croatia's accession to full membership of the European regulatory network, which promotes exchange of information and resources in the area of GMP and provides education for inspectors, will give a new boost to our fi ght against pharmaceutical counterfeiting as a global problem and our to strivings to protect patients. Moreover, international co-operation is heading towards a global inspection framework. The new European legislation in the pipeline will place greater direct responsibility on the manufacturer.
